Results 91 to 100 of about 11,211 (144)

One- and Two-Year Outcomes of Switching to a Dolutegravir-Based ART Regimen: An Observational Emulation of Sequential Target Trials. [PDF]

Open Forum Infect Dis
Zheng A, Murray EJ, Brennan AT, Greener R, Kileel EM, Bor J, Venter WDF, Pisa PT, Fox MP, Maskew M.   +9 more
europepmc   +1 more source

Emerging Dolutegravir Resistance Among Children on Antiretroviral Therapy With Virological Failure in Malawi: Results From a 2023 National Cross-Sectional Survey. [PDF]

J Int AIDS Soc
Bello G, Kabaghe AN, Pals S, Kalata NL, Bighignoli B, van Oosterhout JJ, Mkungudza J, Agyemang E, Zheng DP, Panja L, Matola WB, Chitenje M, Kampira E, Zeh C, Mvula B, Alvarez B, Kagoli M, Mzumara W, Simon KR, Namakhoma I, O'Malley G, Chipeta S, Nyirenda R, da Silva J, Wadonda N, For Malawi HIV Drug Resistance Surveillance Team.   +25 more
europepmc   +1 more source

HIV-1 Resistance to Dolutegravir in Benin: The Need to Improve and Strengthen Therapeutic Patient Education Strategies to Achieve the Third Objective 95 of UNAIDS 95-95-95 Target. [PDF]

Case Rep Infect Dis
Tchiakpe E, Diop-Ndiaye H, Osawe S, Toure-Kane C, Yessoufou A.   +4 more
europepmc   +1 more source

Dolutegravir-Associated Dyslipidemia and Atherogenic Lipid Changes Among Treatment-Naïve People Living With HIV: A 12-Month Prospective Cohort Study From Southern India. [PDF]

Cureus
Sebastian SA, Devasia C, Selvam S, Idiculla J.   +3 more
europepmc   +1 more source

An audit assessing data quality, viral suppression, and transition to dolutegravir among children and adolescents with HIV in care at eThekwini Municipality, South Africa

Hlabisa M, Mtila L, Lushaba N, Tlhaku K, Archary M, van der Molen JS, Mbeje S, Khubone T, Luthuli N, Mahomed S, Garrett N, Lewis L, Dorward J, Sookrajh Y, Brown JA.   +14 more
europepmc   +1 more source

Prevalence and factors associated with anemia among people living with HIV taking dolutegravir-based antiretroviral therapy at debre markos compressive specialized hospital, debre markos, northwest Ethiopia, 2024: A cross-sectional study. [PDF]

Ther Adv Hematol
Jemal M, Yesuf HA, Asfaw MS, Abebe G, Alem A, Geto Z, Kassaw AB, Adugna A, Abebaw D, Malik T, Abera MB, Seid MA.   +11 more
europepmc   +1 more source

Atypical hepatitis B surface antigen escape mutations in an HIV-positive patient in South Africa. [PDF]

S Afr J Infect Dis
Nkosi MB, van Schalkwyk M, Maponga TG, Chili YZ, Muir D, Delport PR, Hugo SS, Ismail Z, Taljaard J, van Zyl GU, Preiser W.   +10 more
europepmc   +1 more source

HIV-1 Sub-subtype A6 Remains Susceptible to Second-Generation Integrase Inhibitors With Limited Emergence of Resistance in Vitro. [PDF]

Open Forum Infect Dis
Saladini F, Giannini A, Giammarino F, Antonova A, Ozhmegova E, Kaiser R, Dragoni F, Boccuto A, Vicenti I, Sönnerborg A, Bobkova M, Zazzi M.   +11 more
europepmc   +1 more source

HIV Resistance to Dolutegravir Varies With Coadministered Agents. [PDF]

Clin Infect Dis
Beck IA, Boyce CL, Bishop MD, Oldroyd AR, du Toit L, Saimen A, Ramarope KM, Hitchcock S, du Plessis NM, Mbogo L, Chohan BH, Maheria P, Oyaro P, Knowles K, Zhang Z, Brummel SS, Drain PK, Smith RA, Gottlieb GS, Abuogi L, Patel RC, Farquhar C, Wiznia A, Ruel TD, Rossouw TM, Hawes SE, Frenkel LM.   +26 more
europepmc   +1 more source

VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment. [PDF]

Open Forum Infect Dis
Ghosn J, Pulido F, Lopardo GD, Olczak A, Ripamonti D, Martin C, Paredes Ceballos O, Stocker H, Mendez Vazquez MJ, Gatanaga H, Metallidis S, Elbirt D, Whitlock G, Mateo González JI, Mohammed P, Wang K, Grove R, Wang R, Jewell A, Sutton K, Elliot E, Moodley R, Borsi R, Jones B, Kisare M, Budnik P, van Wyk J, VOGUE Study Group, VOGUE Study Group .   +28 more
europepmc   +1 more source